These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21892003)

  • 1. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
    Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
    Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
    Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.
    Tsunedomi R; Hazama S; Okayama N; Oka M; Nagano H
    Cancer Sci; 2017 Jul; 108(7):1504-1509. PubMed ID: 28474802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
    Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
    Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
    Huang L; Zhang T; Xie C; Liao X; Yu Q; Feng J; Ma H; Dai J; Li M; Chen J; Zang A; Wang Q; Ge S; Qin K; Cai J; Yuan X
    PLoS One; 2013; 8(10):e77223. PubMed ID: 24143213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
    Salvador-Martín S; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Pachón V; Longo F; Martínez V; Sanjurjo-Sáez M; López-Fernández LA
    Pharmacol Res; 2018 Oct; 136():133-139. PubMed ID: 30213564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
    Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan pathway genotype analysis to predict pharmacokinetics.
    Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
    Treenert A; Areepium N; Tanasanvimon S
    Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
    Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
    Akiyama Y; Fujita K; Ishida H; Sunakawa Y; Yamashita K; Kawara K; Miwa K; Saji S; Sasaki Y
    Drug Metab Pharmacokinet; 2012; 27(3):325-35. PubMed ID: 22201120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
    Kroetz DL
    J Clin Oncol; 2006 Sep; 24(26):4225-7. PubMed ID: 16895999
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
    Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
    Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
    Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
    Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
    World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.
    Tsunedomi R; Hazama S; Fujita Y; Okayama N; Kanekiyo S; Inoue Y; Yoshino S; Yamasaki T; Suehiro Y; Oba K; Mishima H; Sakamoto J; Hamamoto Y; Oka M
    Int J Oncol; 2014 Oct; 45(4):1381-90. PubMed ID: 25175642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
    Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.